What impact could COVID-19-related delays of prostate cancer therapy have on patient survival?


prostate cancer treatment delays

Throughout the pandemic cancer services and treatment have been delayed in order to protect patients from COVID-19 exposure. A new study by researchers from Brigham and Women’s Hospital (MA, USA) investigated the impact of prostate cancer treatment delays for unfavorable intermediate-risk or high-risk localized prostate cancer. Recently published in JAMA Oncology, the results suggest that delaying radiation while remaining on hormone therapy is unlikely to impact on survival. In a cohort of 63,000 cases of localized prostate cancer in the National Cancer Database, the team separated cases into four groups based on when radiation was started relative to hormone therapy....

To view this content, please register now for access

It's completely free